Development of a novel antibody molecule for redirected T cell immunity to tumor cells: The bispecific single chain antibody

Cancer is the one of the leading causes of death in the United States, and will affect one in three people in their lifetime. In addition to existing treatments, immunotherapy is emerging as a potential fourth tier of cancer therapy. The existence of tumor specific proteins and the production of monoclonal antibodies that bind them allow the specific targeting of cancer cells. A promising use for these anti-tumor antibodies involves redirecting a patient's own cytotoxic T cells (CTL) to specifically kill tumor cells by the use of a bispecific antibody. This approach is achieved through the use of bispecific antibodies that bind the T cell and the tumor cell, triggering the specific elimination of the tumor cell. Despite the success of bispecific antibodies and emergence into clinical trials the optimum method of preparing bispecifics has not been resolved.

Name thesis:degree_name

Ph.D.

Level thesis:degree_level

Dissertation

Discipline thesis:degree_discipline

Biochemistry

Grantor

University of Illinois at Urbana-Champaign

Year dc:date

2011

Author dc:creator

• Gruber, Meegan Minori

Contributors dc:contributor

• Kranz, David M.

• Biology, Molecular
• Chemistry, Biochemistry
• Health Sciences, Immunology
• Health Sciences, Oncology

Statement dc:rights

• Copyright 1996 Gruber, Meegan Minori

Language dc:language

eng

Identifier

9780591198812
AAI9712291
(UMI)AAI9712291

OAI identifier oai:identifier

oai:www.ideals.illinois.edu:2142/19278